CA2385849A1 - Applications medicales de formations d'images spectrales par polarisation croisee - Google Patents
Applications medicales de formations d'images spectrales par polarisation croisee Download PDFInfo
- Publication number
- CA2385849A1 CA2385849A1 CA002385849A CA2385849A CA2385849A1 CA 2385849 A1 CA2385849 A1 CA 2385849A1 CA 002385849 A CA002385849 A CA 002385849A CA 2385849 A CA2385849 A CA 2385849A CA 2385849 A1 CA2385849 A1 CA 2385849A1
- Authority
- CA
- Canada
- Prior art keywords
- microcirculation
- ops imaging
- ops
- vessel
- imaging probe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000010287 polarization Effects 0.000 title claims abstract description 39
- 238000000701 chemical imaging Methods 0.000 title description 6
- 238000003384 imaging method Methods 0.000 claims abstract description 412
- 230000017531 blood circulation Effects 0.000 claims abstract description 68
- 230000003595 spectral effect Effects 0.000 claims abstract description 11
- 239000000523 sample Substances 0.000 claims description 230
- 230000004089 microcirculation Effects 0.000 claims description 212
- 210000003743 erythrocyte Anatomy 0.000 claims description 131
- 238000000034 method Methods 0.000 claims description 130
- 238000001356 surgical procedure Methods 0.000 claims description 70
- 230000002792 vascular Effects 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 52
- 108010054147 Hemoglobins Proteins 0.000 claims description 47
- 102000001554 Hemoglobins Human genes 0.000 claims description 47
- 206010047163 Vasospasm Diseases 0.000 claims description 34
- 230000008614 cellular interaction Effects 0.000 claims description 34
- 210000000265 leukocyte Anatomy 0.000 claims description 32
- 238000005534 hematocrit Methods 0.000 claims description 31
- 230000004087 circulation Effects 0.000 claims description 20
- 230000003902 lesion Effects 0.000 claims description 18
- 238000012544 monitoring process Methods 0.000 claims description 16
- 208000009458 Carcinoma in Situ Diseases 0.000 claims description 10
- 210000000601 blood cell Anatomy 0.000 claims description 7
- 210000001772 blood platelet Anatomy 0.000 claims description 6
- 210000003679 cervix uteri Anatomy 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000032843 Hemorrhage Diseases 0.000 claims description 2
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 abstract description 31
- 238000005516 engineering process Methods 0.000 abstract description 30
- 238000011160 research Methods 0.000 abstract description 14
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 239000007787 solid Substances 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 210000004907 gland Anatomy 0.000 abstract 1
- 210000001736 capillary Anatomy 0.000 description 174
- 238000005259 measurement Methods 0.000 description 73
- 210000001519 tissue Anatomy 0.000 description 71
- 208000027418 Wounds and injury Diseases 0.000 description 69
- 206010028980 Neoplasm Diseases 0.000 description 59
- 206010052428 Wound Diseases 0.000 description 58
- 210000003491 skin Anatomy 0.000 description 55
- 230000010412 perfusion Effects 0.000 description 53
- 210000004088 microvessel Anatomy 0.000 description 51
- 201000011461 pre-eclampsia Diseases 0.000 description 47
- 238000001727 in vivo Methods 0.000 description 45
- 241000282414 Homo sapiens Species 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- 238000005286 illumination Methods 0.000 description 36
- 239000003814 drug Substances 0.000 description 32
- 208000014674 injury Diseases 0.000 description 29
- 208000028867 ischemia Diseases 0.000 description 27
- 238000011282 treatment Methods 0.000 description 27
- 230000000283 vasomotion Effects 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 210000002565 arteriole Anatomy 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 210000000264 venule Anatomy 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 230000000747 cardiac effect Effects 0.000 description 24
- 210000002216 heart Anatomy 0.000 description 24
- 238000012800 visualization Methods 0.000 description 24
- 238000003745 diagnosis Methods 0.000 description 23
- 201000010099 disease Diseases 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 229940079593 drug Drugs 0.000 description 20
- 238000011835 investigation Methods 0.000 description 20
- 208000003174 Brain Neoplasms Diseases 0.000 description 19
- 206010058990 Venous occlusion Diseases 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 19
- 206010020772 Hypertension Diseases 0.000 description 18
- 230000004907 flux Effects 0.000 description 18
- 230000010410 reperfusion Effects 0.000 description 18
- 230000008733 trauma Effects 0.000 description 18
- 230000001771 impaired effect Effects 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 241000282412 Homo Species 0.000 description 16
- 230000033115 angiogenesis Effects 0.000 description 16
- 230000006378 damage Effects 0.000 description 16
- 230000002496 gastric effect Effects 0.000 description 16
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 15
- 230000001054 cortical effect Effects 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 239000002158 endotoxin Substances 0.000 description 15
- 238000012771 intravital microscopy Methods 0.000 description 15
- 230000035935 pregnancy Effects 0.000 description 15
- 230000002889 sympathetic effect Effects 0.000 description 15
- 230000029663 wound healing Effects 0.000 description 15
- 230000008859 change Effects 0.000 description 14
- 230000035876 healing Effects 0.000 description 14
- 238000004445 quantitative analysis Methods 0.000 description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 238000012512 characterization method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000011161 development Methods 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- 239000004033 plastic Substances 0.000 description 13
- 230000035939 shock Effects 0.000 description 13
- 230000004075 alteration Effects 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 12
- 230000011514 reflex Effects 0.000 description 12
- 238000005096 rolling process Methods 0.000 description 12
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 208000021328 arterial occlusion Diseases 0.000 description 11
- 231100000284 endotoxic Toxicity 0.000 description 11
- 230000002346 endotoxic effect Effects 0.000 description 11
- 210000003405 ileum Anatomy 0.000 description 11
- 230000033001 locomotion Effects 0.000 description 11
- 210000000496 pancreas Anatomy 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 208000010444 Acidosis Diseases 0.000 description 10
- 206010002329 Aneurysm Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000007950 acidosis Effects 0.000 description 10
- 208000026545 acidosis disease Diseases 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 10
- 238000007675 cardiac surgery Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000002271 resection Methods 0.000 description 10
- 230000004872 arterial blood pressure Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 9
- 238000011156 evaluation Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000001338 necrotic effect Effects 0.000 description 9
- 230000000399 orthopedic effect Effects 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000002798 spectrophotometry method Methods 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- 206010040070 Septic Shock Diseases 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 8
- 239000008148 cardioplegic solution Substances 0.000 description 8
- 239000007850 fluorescent dye Substances 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000005747 tumor angiogenesis Effects 0.000 description 8
- 208000037487 Endotoxemia Diseases 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 208000000558 Varicose Ulcer Diseases 0.000 description 7
- 206010047139 Vasoconstriction Diseases 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 210000003038 endothelium Anatomy 0.000 description 7
- 230000000544 hyperemic effect Effects 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 230000004218 vascular function Effects 0.000 description 7
- 230000025033 vasoconstriction Effects 0.000 description 7
- 238000010989 Bland-Altman Methods 0.000 description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 6
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000002316 cosmetic surgery Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000010191 image analysis Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 230000036303 septic shock Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 5
- 208000028399 Critical Illness Diseases 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 208000012322 Raynaud phenomenon Diseases 0.000 description 5
- 206010063837 Reperfusion injury Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 230000002008 hemorrhagic effect Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 210000001363 mesenteric artery superior Anatomy 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000004963 pathophysiological condition Effects 0.000 description 5
- 230000035479 physiological effects, processes and functions Effects 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- 238000001055 reflectance spectroscopy Methods 0.000 description 5
- 238000000518 rheometry Methods 0.000 description 5
- 210000003786 sclera Anatomy 0.000 description 5
- 208000007056 sickle cell anemia Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 201000009906 Meningitis Diseases 0.000 description 4
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 4
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 4
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 4
- 208000017442 Retinal disease Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 208000008445 altitude sickness Diseases 0.000 description 4
- 230000001772 anti-angiogenic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 210000003238 esophagus Anatomy 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000000050 nutritive effect Effects 0.000 description 4
- 238000009595 pap smear Methods 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- 230000008325 portal venous blood flow Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004895 regional blood flow Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 238000010865 video microscopy Methods 0.000 description 4
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- 241001269524 Dura Species 0.000 description 3
- 206010015866 Extravasation Diseases 0.000 description 3
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 3
- 206010070531 Foetal growth restriction Diseases 0.000 description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000036770 blood supply Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 206010007625 cardiogenic shock Diseases 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 210000000795 conjunctiva Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036251 extravasation Effects 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 208000030941 fetal growth restriction Diseases 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- 238000007455 ileostomy Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 201000004933 in situ carcinoma Diseases 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 238000002350 laparotomy Methods 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- 238000002406 microsurgery Methods 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 230000036513 peripheral conductance Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 210000001147 pulmonary artery Anatomy 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 230000000250 revascularization Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012764 semi-quantitative analysis Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 210000005166 vasculature Anatomy 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000022523 Conjunctival Neoplasms Diseases 0.000 description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241000699673 Mesocricetus auratus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010061548 Red blood cell abnormality Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 2
- 208000019513 White blood cell disease Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002302 brachial artery Anatomy 0.000 description 2
- 210000004781 brain capillary Anatomy 0.000 description 2
- 201000005242 bronchial neoplasm Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000034303 cell budding Effects 0.000 description 2
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 230000000739 chaotic effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000017903 conjunctival tumor Diseases 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 201000005620 dermis tumor Diseases 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000009841 epithelial lesion Effects 0.000 description 2
- 230000004424 eye movement Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 2
- 230000004313 glare Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005205 gut mucosa Anatomy 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 238000011170 pharmaceutical development Methods 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000002278 reconstructive surgery Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000008343 sublingual microcirculation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000006492 vascular dysfunction Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 201000003130 ventricular septal defect Diseases 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- ZWGNFOFTMJGWBF-VZSHSMSCSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid;2-oxopentanedioic acid Chemical compound OC(=O)CCC(=O)C(O)=O.OC(=O)[C@@H](N)CC1=CN=CN1.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 ZWGNFOFTMJGWBF-VZSHSMSCSA-N 0.000 description 1
- TYIRBZOAKBEYEJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetate Chemical compound C1=CC(C)=CC=C1C(=O)C(N1C)=CC=C1CC(=O)OCCN1C(C(=O)N(C)C(=O)N2C)=C2N=C1 TYIRBZOAKBEYEJ-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical compound COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000320529 Allobates femoralis Species 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000035049 Blood-Borne Infections Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 244000038022 Chenopodium capitatum Species 0.000 description 1
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000037194 Fever of Unknown Origin Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 206010022822 Intravascular haemolysis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000027007 Meningioma benign Diseases 0.000 description 1
- 208000004535 Mesenteric Ischemia Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010067013 Normal tension glaucoma Diseases 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041092 Small for dates baby Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 229940092980 adalat Drugs 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 description 1
- 229910001864 baryta Inorganic materials 0.000 description 1
- 201000009467 benign meningioma Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 229960001415 buflomedil Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001101 cardioplegic effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000003788 cerebral perfusion Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000002816 chronic venous insufficiency Diseases 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 238000003702 image correction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 208000024312 invasive carcinoma Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 201000002978 low tension glaucoma Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 230000010060 microvascular dysfunction Effects 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229960001132 naftidrofuryl Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 210000003446 pia mater Anatomy 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000008532 placental abruption Diseases 0.000 description 1
- 238000013439 planning Methods 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 201000005380 purpura fulminans Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 208000022064 reactive hyperemia Diseases 0.000 description 1
- 238000001454 recorded image Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003394 remifentanil Drugs 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14535—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring haematocrit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B3/00—Apparatus for testing the eyes; Instruments for examining the eyes
- A61B3/10—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions
- A61B3/12—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
- A61B3/1241—Objective types, i.e. instruments for examining the eyes independent of the patients' perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes specially adapted for observation of ocular blood flow, e.g. by fluorescein angiography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/413—Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Optics & Photonics (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
L'invention concerne des applications médicales de la technologie de formation d'images spectrales par polarisation croisée. Cette technologie permet d'obtenir une image à contraste élevé de phénomènes sub-superficiels tels que la structure d'un vaisseau sanguin, le flux sanguin dans les vaisseaux, la structure glandulaire, etc. ainsi qu'une image haute résolution de la surface des organes solides. De nombreuses applications cliniques (diagnostique et thérapeutique) ainsi que des applications de cette technologie dans la recherche, dans les domaines médical et pharmaceutique, font également l'objet de cette invention.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15548799P | 1999-09-23 | 1999-09-23 | |
| US60/155,487 | 1999-09-23 | ||
| US20952900P | 2000-06-05 | 2000-06-05 | |
| US60/209,529 | 2000-06-05 | ||
| PCT/US2000/026106 WO2001022741A2 (fr) | 1999-09-23 | 2000-09-22 | Applications medicales de formations d'images spectrales par polarisation croisee |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2385849A1 true CA2385849A1 (fr) | 2001-03-29 |
Family
ID=26852359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002385849A Abandoned CA2385849A1 (fr) | 1999-09-23 | 2000-09-22 | Applications medicales de formations d'images spectrales par polarisation croisee |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2003510112A (fr) |
| AU (1) | AU4022801A (fr) |
| CA (1) | CA2385849A1 (fr) |
| WO (1) | WO2001022741A2 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149416A1 (fr) * | 2015-03-16 | 2016-09-22 | Magic Leap, Inc. | Méthodes et systèmes de diagnostic et de traitement des troubles de santé |
| US10459231B2 (en) | 2016-04-08 | 2019-10-29 | Magic Leap, Inc. | Augmented reality systems and methods with variable focus lens elements |
| US10962855B2 (en) | 2017-02-23 | 2021-03-30 | Magic Leap, Inc. | Display system with variable power reflector |
| ES2975667R1 (es) * | 2021-06-09 | 2024-08-29 | Morel Jose Luis Axel Jerez | Monitor no invasivo del liquido cefalorraquideo y procedimiento de medicion de la presion intracraneal |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135571A0 (en) | 2000-04-10 | 2001-05-20 | Doron Adler | Minimal invasive surgery imaging system |
| US6692430B2 (en) | 2000-04-10 | 2004-02-17 | C2Cure Inc. | Intra vascular imaging apparatus |
| JP5259033B2 (ja) * | 2001-08-03 | 2013-08-07 | オリンパス株式会社 | 内視鏡システム |
| US6922523B2 (en) | 2001-11-08 | 2005-07-26 | Johnson & Johnson Consumer Companies, Inc. | Method of promoting skin care products |
| US6961517B2 (en) | 2001-11-08 | 2005-11-01 | Johnson & Johnson Consumer Companies, Inc. | Method of promoting skin care products |
| US7738032B2 (en) | 2001-11-08 | 2010-06-15 | Johnson & Johnson Consumer Companies, Inc. | Apparatus for and method of taking and viewing images of the skin |
| AU2002360198A1 (en) | 2001-12-11 | 2003-07-09 | C2Cure Inc. | Apparatus, method and system for intravascular photographic imaging |
| AU2003227315A1 (en) * | 2002-04-02 | 2003-10-13 | Yeda Research And Development Co. Ltd. | Characterization of moving objects in a stationary background |
| US8194121B2 (en) | 2002-05-16 | 2012-06-05 | C2Cure, Inc. | Miniature camera head |
| EP1583465A4 (fr) * | 2002-08-28 | 2009-09-16 | Noam Egozi | Detection de bulles de gaz dans un corps vivant |
| CA2539184A1 (fr) * | 2003-09-19 | 2005-03-31 | The General Hospital Corporation | Dispositifs et procedes d'imagerie par polarisation de fluorescence |
| NZ546918A (en) * | 2003-10-03 | 2009-01-31 | Amc Amsterdam | System and method for imaging the reflectance of a substrate |
| CN1897870A (zh) | 2003-12-22 | 2007-01-17 | 皇家飞利浦电子股份有限公司 | 用于进行正交偏振光谱成像(opsi)的装置和方法 |
| US8026942B2 (en) | 2004-10-29 | 2011-09-27 | Johnson & Johnson Consumer Companies, Inc. | Skin imaging system with probe |
| US9131861B2 (en) * | 2004-11-30 | 2015-09-15 | Academisch Medisch Centrum | Pulsed lighting imaging systems and methods |
| US9314164B2 (en) | 2005-10-27 | 2016-04-19 | Northwestern University | Method of using the detection of early increase in microvascular blood content to distinguish between adenomatous and hyperplastic polyps |
| CN101489471B (zh) * | 2006-05-19 | 2014-08-27 | 北岸大学健康系统公司 | 利用检测微血管血液含量早期增大来识别异常组织的装置 |
| US8983570B2 (en) * | 2007-03-27 | 2015-03-17 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treatment of the spine |
| CN101918845B (zh) * | 2007-11-30 | 2014-01-29 | 马斯特里赫特大学 | 评估糖萼状态的方法及其在鉴定血管相关疾病中的应用 |
| US8403862B2 (en) | 2007-12-20 | 2013-03-26 | Yeda Research And Development Co. Ltd. | Time-based imaging |
| JP4789974B2 (ja) * | 2008-05-26 | 2011-10-12 | 順一 金子 | 生体内器官または組織表面に留置可能な近赤外光プローブホルダ |
| JP5503851B2 (ja) * | 2008-07-25 | 2014-05-28 | 株式会社吉田製作所 | マットとその制御方法 |
| JP5582520B2 (ja) * | 2009-02-18 | 2014-09-03 | 国立大学法人名古屋大学 | 血流観測装置 |
| WO2011066546A1 (fr) | 2009-11-30 | 2011-06-03 | The Board Of Trustees Of The University Of Illinois | Evaluation de la circulation microvasculaire |
| WO2012142496A1 (fr) | 2011-04-15 | 2012-10-18 | Constitution Medical, Inc. | Mesure du volume et des constituants de cellules |
| WO2014027293A2 (fr) * | 2012-08-10 | 2014-02-20 | Vita-Sentry Ltd. | Estimations du diamètre interne équivalent d'artérioles |
| ES2949276T3 (es) * | 2013-01-28 | 2023-09-27 | Univ Oslo Hf | Evaluación de la insuficiencia circulatoria |
| WO2016054079A1 (fr) | 2014-09-29 | 2016-04-07 | Zyomed Corp. | Systèmes et procédés pour la détection et la mesure du glucose sanguin du sang et d'autres analytes à l'aide du calcul de collision |
| EP3232778A4 (fr) | 2014-11-24 | 2018-10-10 | Massachusetts Institute of Technology | Systèmes, appareils et procédés d'analyse de la dynamique des cellules sanguines |
| JP6059271B2 (ja) * | 2015-02-26 | 2017-01-11 | サイバネットシステム株式会社 | 画像処理装置及び画像処理方法 |
| FR3049104B1 (fr) * | 2016-03-15 | 2020-02-21 | Universite De Nantes | Procede de diagnostic de maladies inflammatoires chroniques de l'intestin |
| US9554738B1 (en) | 2016-03-30 | 2017-01-31 | Zyomed Corp. | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing |
| WO2017192383A1 (fr) * | 2016-05-02 | 2017-11-09 | Bio-Tree Systems, Inc. | Système et procédé pour la détection d'une maladie rétinienne |
| JP6766449B2 (ja) * | 2016-05-26 | 2020-10-14 | 株式会社ニデック | 医療装置およびプログラム |
| US20170367574A1 (en) * | 2016-06-24 | 2017-12-28 | Verily Life Sciences Llc | Eye cytometer for continuous health monitoring |
| EP3697294B1 (fr) | 2017-10-16 | 2023-12-06 | Massachusetts Institute Of Technology | Système et procédé de mesures hématologiques non invasives |
| DE102018107623A1 (de) * | 2018-03-29 | 2019-10-02 | Imedos Systems GmbH | Verfahren und Vorrichtung zur Untersuchung der neurovaskulären Kopplung im Auge eines Patienten |
| KR102267509B1 (ko) * | 2018-08-29 | 2021-06-21 | 연세대학교 원주산학협력단 | 달팽이관에서의 미세 혈류 측정 방법 및 장치 |
| US11754824B2 (en) | 2019-03-26 | 2023-09-12 | Active Medical, BV | Method and apparatus for diagnostic analysis of the function and morphology of microcirculation alterations |
| KR102364786B1 (ko) * | 2019-05-24 | 2022-02-21 | 서울대학교병원 | 미세순환 정량화 방법 및 장치 |
| KR20200135043A (ko) * | 2019-05-24 | 2020-12-02 | 서울대학교병원 | 마크로파지-1 항원 억제제를 포함하는 폐 손상 질환 예방 또는 치료용 조성물 |
| KR102354222B1 (ko) * | 2019-05-24 | 2022-01-21 | 서울대학교병원 | 미세순환 장애 진단을 위한 정보 제공 방법 및 장치 |
| US20220296108A1 (en) * | 2019-05-24 | 2022-09-22 | Seoul National University Hospital | Method and apparatus for quantitation of microcirculation |
| EP4529839A3 (fr) | 2019-07-24 | 2025-04-16 | Massachusetts Institute of Technology | Inserts de doigt pour dispositif d'imagerie de pliage d'ongles |
| WO2021242983A1 (fr) | 2020-05-28 | 2021-12-02 | Leuko Labs, Inc. | Procédé de détection de globules blancs et/ou de sous-types de globules blancs à partir de vidéos capillaires non invasives |
| WO2022153320A1 (fr) * | 2021-01-18 | 2022-07-21 | Ramot At Tel-Aviv University Ltd. | Procédé et système d'imagerie de vaisseaux sanguins oculaires |
| JP7794589B2 (ja) * | 2021-09-16 | 2026-01-06 | 株式会社トプコン | 眼科装置 |
| CN116385447B (zh) * | 2023-06-07 | 2023-11-24 | 佛山科学技术学院 | 一种甲襞白细胞的监测方法、装置、设备及介质 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5598842A (en) * | 1993-09-03 | 1997-02-04 | Toa Medical Electronics Co., Ltd. | Non-invasive blood analyzer and method using the same |
| JP3267625B2 (ja) * | 1995-10-23 | 2002-03-18 | サイトメトリクス インコーポレイテッド | 反射画像分析の方法および装置 |
-
2000
- 2000-09-22 CA CA002385849A patent/CA2385849A1/fr not_active Abandoned
- 2000-09-22 AU AU40228/01A patent/AU4022801A/en not_active Abandoned
- 2000-09-22 JP JP2001525974A patent/JP2003510112A/ja active Pending
- 2000-09-22 WO PCT/US2000/026106 patent/WO2001022741A2/fr not_active Ceased
Cited By (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10437062B2 (en) | 2015-03-16 | 2019-10-08 | Magic Leap, Inc. | Augmented and virtual reality display platforms and methods for delivering health treatments to a user |
| US10775628B2 (en) | 2015-03-16 | 2020-09-15 | Magic Leap, Inc. | Methods and systems for diagnosing and treating presbyopia |
| US20170007450A1 (en) | 2015-03-16 | 2017-01-12 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for delivery of medication to eyes |
| US20170007843A1 (en) | 2015-03-16 | 2017-01-12 | Magic Leap, Inc. | Methods and systems for diagnosing and treating eyes using laser therapy |
| CN107645921A (zh) * | 2015-03-16 | 2018-01-30 | 奇跃公司 | 用于诊断和治疗健康疾病的方法和系统 |
| US10345591B2 (en) | 2015-03-16 | 2019-07-09 | Magic Leap, Inc. | Methods and systems for performing retinoscopy |
| US10345590B2 (en) | 2015-03-16 | 2019-07-09 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for determining optical prescriptions |
| US10345592B2 (en) | 2015-03-16 | 2019-07-09 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing a user using electrical potentials |
| US10345593B2 (en) | 2015-03-16 | 2019-07-09 | Magic Leap, Inc. | Methods and systems for providing augmented reality content for treating color blindness |
| US10359631B2 (en) | 2015-03-16 | 2019-07-23 | Magic Leap, Inc. | Augmented reality display systems and methods for re-rendering the world |
| US10365488B2 (en) | 2015-03-16 | 2019-07-30 | Magic Leap, Inc. | Methods and systems for diagnosing eyes using aberrometer |
| US10371945B2 (en) | 2015-03-16 | 2019-08-06 | Magic Leap, Inc. | Methods and systems for diagnosing and treating higher order refractive aberrations of an eye |
| US10371947B2 (en) | 2015-03-16 | 2019-08-06 | Magic Leap, Inc. | Methods and systems for modifying eye convergence for diagnosing and treating conditions including strabismus and/or amblyopia |
| US10371946B2 (en) | 2015-03-16 | 2019-08-06 | Magic Leap, Inc. | Methods and systems for diagnosing binocular vision conditions |
| US10371948B2 (en) | 2015-03-16 | 2019-08-06 | Magic Leap, Inc. | Methods and systems for diagnosing color blindness |
| US10371949B2 (en) | 2015-03-16 | 2019-08-06 | Magic Leap, Inc. | Methods and systems for performing confocal microscopy |
| US10379353B2 (en) | 2015-03-16 | 2019-08-13 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing health conditions based on visual fields |
| US10379351B2 (en) | 2015-03-16 | 2019-08-13 | Magic Leap, Inc. | Methods and systems for diagnosing and treating eyes using light therapy |
| US10379350B2 (en) | 2015-03-16 | 2019-08-13 | Magic Leap, Inc. | Methods and systems for diagnosing eyes using ultrasound |
| US10379354B2 (en) | 2015-03-16 | 2019-08-13 | Magic Leap, Inc. | Methods and systems for diagnosing contrast sensitivity |
| US10386641B2 (en) | 2015-03-16 | 2019-08-20 | Magic Leap, Inc. | Methods and systems for providing augmented reality content for treatment of macular degeneration |
| US10386640B2 (en) | 2015-03-16 | 2019-08-20 | Magic Leap, Inc. | Methods and systems for determining intraocular pressure |
| US10386639B2 (en) | 2015-03-16 | 2019-08-20 | Magic Leap, Inc. | Methods and systems for diagnosing eye conditions such as red reflex using light reflected from the eyes |
| US10429649B2 (en) | 2015-03-16 | 2019-10-01 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing using occluder |
| US20170000342A1 (en) | 2015-03-16 | 2017-01-05 | Magic Leap, Inc. | Methods and systems for detecting health conditions by imaging portions of the eye, including the fundus |
| US12345892B2 (en) | 2015-03-16 | 2025-07-01 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing health conditions based on visual fields |
| WO2016149416A1 (fr) * | 2015-03-16 | 2016-09-22 | Magic Leap, Inc. | Méthodes et systèmes de diagnostic et de traitement des troubles de santé |
| US10459229B2 (en) | 2015-03-16 | 2019-10-29 | Magic Leap, Inc. | Methods and systems for performing two-photon microscopy |
| US10466477B2 (en) | 2015-03-16 | 2019-11-05 | Magic Leap, Inc. | Methods and systems for providing wavefront corrections for treating conditions including myopia, hyperopia, and/or astigmatism |
| US10473934B2 (en) | 2015-03-16 | 2019-11-12 | Magic Leap, Inc. | Methods and systems for performing slit lamp examination |
| US10527850B2 (en) | 2015-03-16 | 2020-01-07 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for determining optical prescriptions by imaging retina |
| US10539795B2 (en) | 2015-03-16 | 2020-01-21 | Magic Leap, Inc. | Methods and systems for diagnosing and treating eyes using laser therapy |
| US10539794B2 (en) | 2015-03-16 | 2020-01-21 | Magic Leap, Inc. | Methods and systems for detecting health conditions by imaging portions of the eye, including the fundus |
| US10545341B2 (en) | 2015-03-16 | 2020-01-28 | Magic Leap, Inc. | Methods and systems for diagnosing eye conditions, including macular degeneration |
| US10564423B2 (en) | 2015-03-16 | 2020-02-18 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for delivery of medication to eyes |
| US10451877B2 (en) | 2015-03-16 | 2019-10-22 | Magic Leap, Inc. | Methods and systems for diagnosing and treating presbyopia |
| US10788675B2 (en) | 2015-03-16 | 2020-09-29 | Magic Leap, Inc. | Methods and systems for diagnosing and treating eyes using light therapy |
| US10969588B2 (en) | 2015-03-16 | 2021-04-06 | Magic Leap, Inc. | Methods and systems for diagnosing contrast sensitivity |
| US10983351B2 (en) | 2015-03-16 | 2021-04-20 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing health conditions based on visual fields |
| US11156835B2 (en) | 2015-03-16 | 2021-10-26 | Magic Leap, Inc. | Methods and systems for diagnosing and treating health ailments |
| US11256096B2 (en) | 2015-03-16 | 2022-02-22 | Magic Leap, Inc. | Methods and systems for diagnosing and treating presbyopia |
| US11747627B2 (en) | 2015-03-16 | 2023-09-05 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing health conditions based on visual fields |
| US11474359B2 (en) | 2015-03-16 | 2022-10-18 | Magic Leap, Inc. | Augmented and virtual reality display systems and methods for diagnosing health conditions based on visual fields |
| US10444504B2 (en) | 2015-03-16 | 2019-10-15 | Magic Leap, Inc. | Methods and systems for performing optical coherence tomography |
| US11106041B2 (en) | 2016-04-08 | 2021-08-31 | Magic Leap, Inc. | Augmented reality systems and methods with variable focus lens elements |
| US11614626B2 (en) | 2016-04-08 | 2023-03-28 | Magic Leap, Inc. | Augmented reality systems and methods with variable focus lens elements |
| US10459231B2 (en) | 2016-04-08 | 2019-10-29 | Magic Leap, Inc. | Augmented reality systems and methods with variable focus lens elements |
| US10962855B2 (en) | 2017-02-23 | 2021-03-30 | Magic Leap, Inc. | Display system with variable power reflector |
| US11774823B2 (en) | 2017-02-23 | 2023-10-03 | Magic Leap, Inc. | Display system with variable power reflector |
| US11300844B2 (en) | 2017-02-23 | 2022-04-12 | Magic Leap, Inc. | Display system with variable power reflector |
| ES2975667R1 (es) * | 2021-06-09 | 2024-08-29 | Morel Jose Luis Axel Jerez | Monitor no invasivo del liquido cefalorraquideo y procedimiento de medicion de la presion intracraneal |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001022741A2 (fr) | 2001-03-29 |
| JP2003510112A (ja) | 2003-03-18 |
| WO2001022741A3 (fr) | 2001-10-04 |
| AU4022801A (en) | 2001-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2385849A1 (fr) | Applications medicales de formations d'images spectrales par polarisation croisee | |
| JP4615865B2 (ja) | 静止したバックグラウンド中の移動物質の特徴づけ | |
| US10987011B2 (en) | Assessing circulatory failure | |
| US20080021331A1 (en) | Characterization of moving objects in a stationary background | |
| JP2010538785A (ja) | 撮像装置および方法 | |
| Schraven et al. | Continuous intraoperative perfusion monitoring of free microvascular anastomosed fasciocutaneous flaps using remote photoplethysmography | |
| De Bruin et al. | Can sidestream dark field (SDF) imaging identify subtle microvascular changes of the bowel during colorectal surgery? | |
| Friedland et al. | Measurement of mucosal capillary hemoglobin oxygen saturation in the colon by reflectance spectrophotometry | |
| Fu et al. | Rapid, label-free detection of cerebral ischemia in rats using hyperspectral imaging | |
| Vardhan et al. | Techniques for diagnosing anastomotic leaks intraoperatively in colorectal surgeries: a review | |
| RU2580895C2 (ru) | Способ оценки регионарного кровообращения, тканевой микроциркуляции и насыщения крови кислородом и устройство для оценки регионарного кровообращения, тканевой микроциркуляции и насыщения крови кислородом | |
| Betz et al. | Endoscopic measurements of free-flap perfusion in the head and neck region using red-excited Indocyanine Green: preliminary results | |
| US20210350927A1 (en) | Assessing circulatory failure | |
| Podolyan et al. | Imaging photoplethysmography quantifies endothelial dysfunction in patients with risk factors for cardiovascular complications | |
| Kamshilin et al. | Imaging photoplethysmography and its applications | |
| Su et al. | Assessment of mucosal hemodynamics in normal human colon and patients with inflammatory bowel disease | |
| Kam et al. | Fluorescein-assisted laparoscopy in the identification of arterial mesenteric ischemia | |
| Gareau et al. | Optical fiber probe spectroscopy for laparoscopic monitoring of tissue oxygenation during esophagectomies | |
| Berggren et al. | Perfusion monitoring during oculoplastic reconstructive surgery: a comprehensive review | |
| Tang et al. | In vivo Doppler optical coherence tomography of mucocutaneous telangiectases in hereditary hemorrhagic telangiectasia | |
| Adamenkov et al. | Intraoperative evaluation of the intestinal wall viability | |
| Widaeus et al. | Noninvasive Bedside Approaches for Assessing Microvascular Dysfunction | |
| RU2622983C1 (ru) | Способ интраоперационной визуализации ишемически-реперфузионного повреждения миокарда | |
| Tugtekin et al. | Endotoxin-induced ileal mucosal acidosis is associated with impaired villus microcirculation in pigs | |
| Kamshilin | Imaging Photoplethysmography as a Reliable Tool for Monitoring Tissue Perfusion during Open Brain and Abdominal Surgeries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |